ClinicalTrials.gg
CompletedNCT01777282Updated May 3, 2017Results posted

A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Albiglutide and Sulfonylurea in Diabetes Mellitus, sponsored by GlaxoSmithKline. Completed at 49 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-05-03.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
374
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Diabetes Mellitus by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · GlaxoSmithKline.

Enrollment
8th of 33
374 · median 78
Started
2013
with 2 others
Phase 3
11 of 38
none open now
Registered
32nd of 38
by date

Among the 38 studies in Diabetes Mellitus by GlaxoSmithKline, this one is the 8th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2013, is one of 11 in phase 3, and was the 32nd registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 38 studies in Diabetes Mellitus by GlaxoSmithKline is open now. The open studies under Diabetes Mellitus, anywhere →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 38 studies in Diabetes Mellitus by GlaxoSmithKline as a file.
02

Study summary

This study is designed to examine the long term safety and efficacy of weekly subcutaneously injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in Japanese subjects with type 2 diabetes mellitus.

Read the detailed description

This study is designed to examine the long term safety and efficacy of weekly subcutaneously injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in Japanese subjects with type 2 diabetes mellitus. Subjects with a historical diagnosis of type 2 diabetes mellitus who are inadequately controlled on a single oral antidiabetic agent will be recruited into the study. Subjects will continue on their single antidiabetic agent and once weekly albiglutide will be added.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

Keywords

  • albiglutide
  • Japanese
  • glucagon-like peptide-1
  • GSK716155
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with diagnosis of Type 2 Diabetes Mellitus, who are experiencing inadequate glycemic control and receiving treatment with a stable dose of a single oral antidiabetic medication
  • (BMI) 17 to 40 kg/ m2 inclusive
  • Subjects with an between 7.0% and 10.0% at Screening
  • >30 mL/min (calculated using the Cockcroft-Gault formula)

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes mellitus
  • Female subject is pregnant, lactating, or \<6 weeks postpartum
  • cardiovascular and/or cerebrovascular disease
  • Current ongoing symptomatic biliary disease, clinical signs or symptoms of pancreatitis, or a history of chronic or acute pancreatitis, as determined by the investigator
  • Serum amylase >=3 × and/or serum lipase >=2 × ULN and/or subject is experiencing any symptoms possibly related to pancreatitis
  • Prior use of a GLP-1R agonist or DPP-IV inhibitor within 6 months before Screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
374 participants (actual)

Study arms

  • Active comparator
    Albiglutide + Sulfonylurea

    Albiglutide in combination with background sulfonylurea

    Drug: Albiglutide · Drug: Sulfonylurea

  • Active comparator
    Albiglutide + Biguanide

    Albiglutide in combination with background biguanide

    Drug: Albiglutide · Drug: Biguanide

  • Active comparator
    Albiglutide + Glinide

    Albiglutide in combination with background glinide

    Drug: Albiglutide · Drug: Glinide

  • Active comparator
    Albiglutide + Thiazolidinedione

    Albiglutide in combination with background thiazolidinedione

    Drug: Albiglutide · Drug: Thiazolidinedione

  • Active comparator
    Albiglutide + Alpha-glucosidase inhibitor

    Albiglutide in combination with background alpha-glucosidase inhibitor

    Drug: Albiglutide · Drug: Alpha-glucosidase inhibitor

Interventions

  • Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.

  • DrugSulfonylurea

    Drug pages: Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea

    Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.

  • Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.

  • DrugGlinide

    Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.

  • Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.

  • Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of non-serious AEs and SAEs. Non-serious hypoglycemia events are not included.

    Time frame: From Baseline through Week 52

  2. Number of Participants With Any Hypoglycemic Event

    Hypoglycemia events are defined with respect to low plasma glucose level, mostly accompanied by typical symptoms and/or assistance needed from third party with glucose administration. These events were reported by the investigators upon verification of the plasma glucose levels, symptoms and assistance recorded by the participants, and/or plasma glucose values obtained from laboratory evaluations.

    Time frame: From Baseline through Week 52

Secondary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the value at Week 52 minus the value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline HbA1c observation carried forward for the analysis.

    Time frame: Baseline and Week 52

  2. Percentage of Participants Achieving Clinically Meaningful Levels of HbA1c (i.e., the Percentage of Participants Achieving Treatment Goal of <6.5% and <7.0% at Week 52)

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline HbA1c observation carried forward for the analysis. Clinically meaningful levels of response in HbA1c are defined as \<6.5% and \<7.0%.

    Time frame: Week 52

  3. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52

    FPG is an indicator of efficacy. The Baseline FPG value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the FPG value at Week 52 minus the FPG value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline FPG observation carried forward for the analysis.

    Time frame: Baseline and Week 52

  4. Change From Baseline in Body Weight at Week 52

    The Baseline body weight value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the body weight value at Week 52 minus the value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline weight observation carried forward for the analysis.

    Time frame: Baseline and Week 52

  5. Time to Study Withdrawal Due to Hyperglycemia

    Participants who experienced persistent hyperglycemia after uptitration were to be withdrawn from the study. Hyperglycemia is defined as a fasting plasma glucose \>=280 mg/dL (\>=15.5 mmol/L) from \>=Week 2 to \<Week 12 or \>=230 mg/dL (\>=12.8 mmol/L) from \>=Week 12 to \<Week 52.

    Time frame: Week 52

07

Results

Posted Oct 14, 2015

Participant flow

A total of 360 participants with type 2 diabetes mellitus (T2DM) were planned and 374 participants were enrolled and analyzed in the Safety Population; the Safety Population and Intent-to-Treat Population were identical in this study.

Participant flow — Overall Study
MilestoneAlbiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)
Started12067656161
Completing treatment period10963595954
Completing follow-up period10963595954
Completed10963595954
Not completed114627
Withdrew: Persistent hyperglycemia00100
Withdrew: New antidiabetic medication00100
Withdrew: Adverse event44213
Withdrew: Withdrawal by subject40012
Withdrew: Protocol violation20102
Withdrew: Moved, transfer abroad, did not enter fu10100

Outcome measures

PrimaryNumber of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE)

An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of non-serious AEs and SAEs. Non-serious hypoglycemia events are not included.

Time frame:
From Baseline through Week 52
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE)
ParticipantsAlbiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)
Any AE9747584943
Any SAE20123
PrimaryNumber of Participants With Any Hypoglycemic Event

Hypoglycemia events are defined with respect to low plasma glucose level, mostly accompanied by typical symptoms and/or assistance needed from third party with glucose administration. These events were reported by the investigators upon verification of the plasma glucose levels, symptoms and assistance recorded by the participants, and/or plasma glucose values obtained from laboratory evaluations.

Time frame:
From Baseline through Week 52
Reported as:
Number · Participants
Number of Participants With Any Hypoglycemic Event
ParticipantsAlbiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)
Number of Participants With Any Hypoglycemic Event171420
SecondaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the value at Week 52 minus the value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline HbA1c observation carried forward for the analysis.

Time frame:
Baseline and Week 52
Reported as:
Mean · Percentage of HbA1c in the blood
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52
Percentage of HbA1c in the bloodAlbiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52-1.04 ± 0.657-0.94 ± 0.623-0.95 ± 0.836-1.42 ± 0.771-1.39 ± 0.770
SecondaryPercentage of Participants Achieving Clinically Meaningful Levels of HbA1c (i.e., the Percentage of Participants Achieving Treatment Goal of <6.5% and <7.0% at Week 52)

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline HbA1c observation carried forward for the analysis. Clinically meaningful levels of response in HbA1c are defined as \<6.5% and \<7.0%.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinically Meaningful Levels of HbA1c (i.e., the Percentage of Participants Achieving Treatment Goal of <6.5% and <7.0% at Week 52)
Percentage of participantsAlbiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)
HbA1c <6.5%20.026.924.645.926.2
HbA1c <7.0%54.259.752.380.367.2
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 52

FPG is an indicator of efficacy. The Baseline FPG value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the FPG value at Week 52 minus the FPG value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline FPG observation carried forward for the analysis.

Time frame:
Baseline and Week 52
Reported as:
Mean · Milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52
Milligrams per deciliter (mg/dL)Albiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52-16.4 ± 28.52-24.3 ± 19.98-16.4 ± 30.37-32.1 ± 27.21-33.2 ± 28.38
SecondaryChange From Baseline in Body Weight at Week 52

The Baseline body weight value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the body weight value at Week 52 minus the value at Baseline. Participants who discontinued from study treatment before Week 52 had their last on-treatment, post-Baseline weight observation carried forward for the analysis.

Time frame:
Baseline and Week 52
Reported as:
Mean · Kilograms (kg)
Change From Baseline in Body Weight at Week 52
Kilograms (kg)Albiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)
Change From Baseline in Body Weight at Week 520.25 ± 2.167-0.33 ± 2.082-0.04 ± 2.4050.52 ± 2.823-0.13 ± 2.620
SecondaryTime to Study Withdrawal Due to Hyperglycemia

Participants who experienced persistent hyperglycemia after uptitration were to be withdrawn from the study. Hyperglycemia is defined as a fasting plasma glucose \>=280 mg/dL (\>=15.5 mmol/L) from \>=Week 2 to \<Week 12 or \>=230 mg/dL (\>=12.8 mmol/L) from \>=Week 12 to \<Week 52.

Time frame:
Week 52
Reported as:
Mean · Weeks
Time to Study Withdrawal Due to Hyperglycemia
WeeksAlbiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)
Time to Study Withdrawal Due to Hyperglycemia13.0 ± NA—16.5 ± 3.54——

Adverse events

Collected over On-therapy non-serious adverse events (AEs) and serious adverse events (SAEs) with an onset date on or after the start date of study treatment and within 56 days after the date of the last dose of study treatment, are summarized through Week 52.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Albiglutide Plus (+) Background OAD (Sulfonylurea)—2/120 (1.7%)68/120 (56.7%)
Albiglutide Plus (+) Background OAD (Biguanide)—0/67 (0%)31/67 (46.3%)
Albiglutide Plus (+) Background OAD (Glinide)—1/65 (1.5%)38/65 (58.5%)
Albiglutide Plus (+) Background OAD (Thiazolidinedione)—2/61 (3.3%)35/61 (57.4%)
Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)—3/61 (4.9%)24/61 (39.3%)
Most frequent serious events
Most frequent serious events
EventAlbiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)
Femur fractureInjury, poisoning and procedural complications0/1200/670/650/611/61
Foot fractureInjury, poisoning and procedural complications0/1200/670/651/610/61
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1200/670/651/610/61
Chest discomfortGeneral disorders0/1200/670/650/611/61
CholelithiasisHepatobiliary disorders0/1200/670/650/611/61
Colon AdenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1200/671/650/610/61
Anal abscessInfections and infestations1/1200/670/650/610/61
Urinary tract infectionInfections and infestations1/1200/670/650/610/61
Most frequent other events
Most frequent other events
EventAlbiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)
NasopharyngitisInfections and infestations37/12019/6730/6519/6117/61
HypoglycaemiaMetabolism and nutrition disorders17/1201/674/652/610/61
ConstipationGastrointestinal disorders15/1201/674/655/612/61
DiarrhoeaGastrointestinal disorders3/1206/671/650/612/61
Diabetic retinopathyEye disorders8/1203/670/655/614/61
Back painMusculoskeletal and connective tissue disorders4/1202/671/655/610/61
ContusionInjury, poisoning and procedural complications8/1200/671/650/610/61
PharyngitisInfections and infestations4/1202/672/654/612/61
BronchitisInfections and infestations4/1204/671/652/613/61
GastroenteritisInfections and infestations6/1201/672/652/610/61

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Albiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)Total
Mean58.5 ± 9.1957.0 ± 8.5555.7 ± 11.0759.0 ± 10.5457.4 ± 10.4757.7 ± 9.89
Sex: Female, Male
Sex: Female, Male(Participants)Albiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)Total
Female3322221120108
Male8745435041266
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Albiglutide Plus (+) Background OAD (Sulfonylurea)Albiglutide Plus (+) Background OAD (Biguanide)Albiglutide Plus (+) Background OAD (Glinide)Albiglutide Plus (+) Background OAD (Thiazolidinedione)Albiglutide Plus (+) Background OAD (α-Glucosidase Inhibitor)Total
Asian - Japanese Heritage12067656161374
08

Study locations

49 sites
  • GSK Investigational Site
    Aichi, 456-0058, Japan
  • GSK Investigational Site
    Chiba, 263-0043, Japan
  • GSK Investigational Site
    Ehime, 792-8586, Japan
  • GSK Investigational Site
    Fukuoka, 810-0014, Japan
  • GSK Investigational Site
    Fukuoka, 815-8588, Japan
  • GSK Investigational Site
    Fukuoka, 819-0168, Japan
  • GSK Investigational Site
    Fukushima, 960-0418, Japan
  • GSK Investigational Site
    Fukushima, 963-8851, Japan
  • GSK Investigational Site
    Gunma, 370-3573, Japan
  • GSK Investigational Site
    Gunma, 379-0116, Japan
  • GSK Investigational Site
    Hokkaido, 040-8585, Japan
  • GSK Investigational Site
    Hokkaido, 070-0002, Japan
  • GSK Investigational Site
    Ibaraki, 300-0835, Japan
  • GSK Investigational Site
    Ibaraki, 311-0113, Japan
  • GSK Investigational Site
    Kagawa, 760-0076, Japan
  • GSK Investigational Site
    Kagoshima, 890-0061, Japan
  • GSK Investigational Site
    Kanagawa, 232-0064, Japan
  • GSK Investigational Site
    Kanagawa, 235-0045, Japan
  • GSK Investigational Site
    Kanagawa, 252-0302, Japan
  • GSK Investigational Site
    Kanagawa, 253-0044, Japan
  • GSK Investigational Site
    Kochi, 780-0088, Japan
  • GSK Investigational Site
    Kumamoto, 862-0960, Japan
  • GSK Investigational Site
    Kumamoto, 867-0041, Japan
  • GSK Investigational Site
    Kyoto, 600-8558, Japan
  • GSK Investigational Site
    Kyoto, 601-1495, Japan
  • GSK Investigational Site
    Kyoto, 601-8325, Japan
  • GSK Investigational Site
    Miyagi, 980-0021, Japan
  • GSK Investigational Site
    Miyagi, 985-0852, Japan
  • GSK Investigational Site
    Nagano, 399-0006, Japan
  • GSK Investigational Site
    Nagano, 399-0036, Japan
  • GSK Investigational Site
    Oita, 870-0039, Japan
  • GSK Investigational Site
    Okinawa, 900-0029, Japan
  • GSK Investigational Site
    Osaka, 530-0012, Japan
  • GSK Investigational Site
    Osaka, 536-0023, Japan
  • GSK Investigational Site
    Osaka, 538-0044, Japan
  • GSK Investigational Site
    Osaka, 577-0803, Japan
  • GSK Investigational Site
    Osaka, 582-0019, Japan
  • GSK Investigational Site
    Saitama, 332-0012, Japan
  • GSK Investigational Site
    Saitama, 350-0035, Japan
  • GSK Investigational Site
    Saitama, 350-0851, Japan
  • GSK Investigational Site
    Saitama, 354-0031, Japan
  • GSK Investigational Site
    Saitama, 355-0321, Japan
  • GSK Investigational Site
    Saitama, 358-0011, Japan
  • GSK Investigational Site
    Shizuoka, 424-0855, Japan
  • GSK Investigational Site
    Tochigi, 329-0433, Japan
  • GSK Investigational Site
    Tokyo, 103-0002, Japan
  • GSK Investigational Site
    Tokyo, 103-0027, Japan
  • GSK Investigational Site
    Tokyo, 125-0054, Japan
  • GSK Investigational Site
    Tokyo, 143-0015, Japan
09

References and documents

Publications

  • Okuda I, Wilson TH, Yue L, Nakajima H, Carr MC, Tsuboi M, Nino A, Seino Y. Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs. Curr Med Res Opin. 2017 Mar;33(3):431-438. doi: 10.1080/03007995.2016.1261817. Epub 2016 Dec 21. PubMed 27852119 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Jan 2015, 23 months.

Results were first posted in Oct 2015, 8 months after primary completion.

Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 23 months is above that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2013
First posted
Jan 28, 2013
StartActual
Feb 23, 2013
Primary completionActual
Jan 27, 2015
CompletionActual
Jan 27, 2015
Results first posted
Oct 14, 2015
Last update
May 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01777282
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 28, 2013
Start date
Feb 23, 2013
Primary completion
Jan 27, 2015
Completion
Jan 27, 2015
Results posted
Oct 14, 2015
Last update
May 3, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea · Biguanides · 2,4-thiazolidinedione · Alpha-glucosidase inhibitors

Start the discussion